Invanz(ertapenem)
Ertapenem, Invanz (ertapenem) is a small molecule pharmaceutical. Ertapenem was first approved as Invanz on 2001-11-21. It is used to treat abdominal abscess, bacterial infections, bacteroides infections, escherichia coli infections, and haemophilus infections amongst others in the USA. It has been approved in Europe to treat bacterial infections, bacterial pneumonia, community-acquired infections, gram-negative bacterial infections, and staphylococcal infections amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Ertapenem, Invanz (discontinued: Ertapenem)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ertapenem sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVANZ | Merck & Co | N-021337 RX | 2001-11-21 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ertapenam | ANDA | 2021-05-27 |
| ertapenem | ANDA | 2025-09-03 |
| ertapenem sodium | ANDA | 2024-12-17 |
| invanz | New Drug Application | 2024-02-15 |
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1335 | Injection, ertapenem sodium, 500 mg |
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | 5 | 1 | — | 8 |
| Communicable diseases | D003141 | — | — | — | 1 | 4 | 1 | — | 6 |
| Intraabdominal infections | D059413 | — | — | — | 1 | 2 | 1 | — | 4 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 1 | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | 1 | — | 1 |
| Immediate hypersensitivity | D006969 | — | — | — | — | — | 1 | — | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
| Continuous ambulatory peritoneal dialysis | D010531 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 4 | — | 1 | 6 |
| Surgical wound infection | D013530 | — | — | — | 1 | 2 | — | — | 2 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 1 | — | — | 2 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Soft tissue infections | D018461 | — | — | — | 1 | — | — | — | 1 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | — | — | — | 1 |
| Pelvic infection | D034161 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ertapenem |
| INN | ertapenem |
| Description | Ertapenem is meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract. It has a role as an antibacterial drug. It is a carbapenemcarboxylic acid and a pyrrolidinecarboxamide. It is a conjugate acid of an ertapenem(1-). |
| Classification | Small molecule |
| Drug class | antibacterial antibiotics, carbapenem derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 153832-46-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1359 |
| ChEBI ID | 404903 |
| PubChem CID | 150610 |
| DrugBank | DB00303 |
| UNII ID | G32F6EID2H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Invanz – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,886 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,772 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use